Expert Commentary Backs Negative Cannabis Trial for Brachial Plexus Pain

An invited orthopaedic surgery expert endorses a rigorous RCT’s finding that cannabis-based medicine adds no meaningful benefit for brachial plexus neuropathic pain, while urging continued research into pain mechanisms and novel analgesics for chronic neuropathic conditions.

Why This Matters

Brachial plexus injuries produce some of the most severe and treatment-resistant neuropathic pain syndromes encountered in orthopaedic and rehabilitation practice. As cannabis-based medicines gain legal access and patient interest worldwide, clinicians face growing pressure to offer or endorse these products for refractory pain. When a well-designed randomized controlled trial returns a clearly negative result for a specific neuropathic pain population, expert contextualization of that finding matters enormously, both to prevent premature clinical adoption and to avoid prematurely closing avenues of legitimate research.

Clinical Summary

Chronic neuropathic pain following traumatic brachial plexus injury remains a formidable clinical challenge, often poorly responsive to standard analgesic regimens. In a CORR Insights commentary published in Clinical Orthopaedics and Related Research, Pierre Hoffmeyer, Emeritus Professor of Orthopaedic Surgery at the University of Geneva, evaluates the findings of a triple-blind, crossover randomized controlled trial by Kittithamvongs and colleagues. That trial assessed cannabis drops as adjuvant therapy in 28 male patients with severe traumatic brachial plexus injuries, measuring outcomes across nociceptive pain (VAS), neuropathic pain (DN4), and sleep quality over a 14-day crossover period. The biological rationale centers on the endocannabinoid system’s role in pain modulation, which has prompted interest in cannabinoid-based therapies across multiple neuropathic pain conditions.

The referenced RCT found no clinically important benefit of cannabis-based medicine on any measured outcome. Hoffmeyer endorses this conclusion and frames it as scientifically valuable, noting that solid negative evidence helps surgeons avoid raising false hopes and administering futile therapies. However, he carefully limits the scope of this interpretation: the trial enrolled only male patients with a single, specific mechanism of nerve injury, and its results should not be generalized to other neuropathic pain populations or cannabinoid formulations. The commentary identifies the need for future genetics-informed, mechanism-focused analgesic research and calls for orthopaedic surgeons to develop greater pharmacological literacy regarding multimodal pain management.

Dr. Caplan’s Take

This commentary does something genuinely useful: it takes a clean negative result and prevents both overreaction and underreaction. Patients with brachial plexus injuries who ask about cannabis are often desperate, having exhausted conventional options. An honest response requires acknowledging that a well-designed trial found no benefit in their specific condition, while also explaining that pain neurobiology is complex and this finding does not settle the broader question of cannabinoids in neuropathic pain. The gap between mechanistic plausibility and clinical proof remains wide.

In practice, when I see patients with refractory brachial plexus neuropathic pain, I do not recommend cannabis-based medicine as a first-line or adjuvant therapy based on current evidence. I focus on optimizing established neuropathic pain pharmacotherapy, incorporating physical rehabilitation, and ensuring adequate psychological support. If a patient is already using cannabis, I discuss the evidence honestly and monitor rather than dismiss. The goal is always to keep the therapeutic relationship intact while being truthful about what we know and what we do not.

Clinical Perspective

This commentary sits at a critical juncture in the cannabinoid-pain research arc. The referenced trial is notable for its rigorous triple-blind crossover design, but it studied a narrow population: 28 male patients with a single injury type. Hoffmeyer rightly warns against extrapolating this negative finding to all neuropathic pain states. For clinicians, the evidence currently does not support recommending cannabis-based medicine for brachial plexus neuropathic pain specifically, but neither does this single trial invalidate cannabinoid research for conditions with different underlying mechanisms, receptor expression profiles, or patient demographics.

From a pharmacological standpoint, cannabis-based medicines carry their own consideration set, including variable bioavailability of oral formulations, potential interactions with gabapentinoids and opioids commonly used in this population, and psychoactive effects that may complicate rehabilitation. The 14-day crossover period in the referenced trial may also have been insufficient to capture delayed analgesic effects, though the commentary does not address this directly. The single most actionable recommendation for clinicians now is to cite this negative trial explicitly when counseling brachial plexus injury patients about cannabis, while supporting referral to multidisciplinary pain programs that can offer evidence-based multimodal regimens.

Study at a Glance

Study Type

Invited expert commentary (CORR Insights)

Population

Commentary on RCT of 28 male patients with severe traumatic brachial plexus injuries

Intervention

Cannabis drops versus placebo (14-day crossover, as described in referenced RCT)

Comparator

Placebo (crossover design)

Primary Outcomes

VAS (nociceptive pain), DN4 (neuropathic pain), sleep quality

Sample Size

28 patients in referenced RCT (two groups of 14)

Journal

Clinical Orthopaedics and Related Research

Year

2024

DOI or PMID

Referenced RCT: DOI 10.1097/CORR.0000000000003221

Funding Source

Not reported; no conflicts of interest declared by commentator

What Kind of Evidence Is This

This is an invited expert commentary, not primary research. It occupies one of the lower tiers in the evidence hierarchy, representing the informed scholarly opinion of a single emeritus professor of orthopaedic surgery. The most important inference constraint is that the commentary presents no original data and performs no independent appraisal of the referenced RCT’s methodology, statistical power, or blinding integrity. Its conclusions carry the weight of clinical experience but cannot independently establish or refute efficacy claims.

How This Fits With the Broader Literature

The broader literature on cannabinoids for neuropathic pain is mixed and condition-dependent. Some systematic reviews, including work by Mücke and colleagues (2018), have found modest short-term analgesic effects in certain neuropathic pain populations, while others have highlighted inconsistent results and significant adverse effect profiles. The referenced RCT’s negative finding in brachial plexus injury aligns with a growing recognition that cannabinoid efficacy may be highly condition-specific, and that positive results in one neuropathic pain context do not transfer automatically to another. Hoffmeyer’s commentary reinforces this nuance without attempting a comprehensive evidence synthesis.

Common Misreadings

The most likely overinterpretation is reading this commentary as definitive proof that cannabinoids are ineffective for all neuropathic pain. Hoffmeyer himself explicitly cautions against this generalization, noting the trial’s male-only enrollment and condition-specific design. A single negative RCT in 28 patients with one type of nerve injury, however well-designed, cannot close the question of cannabinoid analgesia across the full spectrum of neuropathic pain conditions. Equally, the commentary’s endorsement should not be mistaken for an independent systematic appraisal of the trial’s quality.

Bottom Line

This expert commentary responsibly endorses a rigorous negative RCT, confirming that cannabis-based medicine does not provide clinically meaningful benefit for brachial plexus neuropathic pain. It does not establish that cannabinoids are ineffective for all neuropathic pain conditions. For clinicians treating brachial plexus injury patients, the current evidence supports focusing on established multimodal pain strategies rather than cannabis-based adjuvant therapy.

References

1. Kittithamvongs P, et al. Cannabis-based medicine as adjuvant therapy for neuropathic pain in brachial plexus injury: a triple-blind crossover randomized controlled trial. Clinical Orthopaedics and Related Research. 2024. DOI: 10.1097/CORR.0000000000003221.
2. Hoffmeyer P. CORR Insights: Cannabis-based medicine as adjuvant therapy for neuropathic pain in brachial plexus injury. Clinical Orthopaedics and Related Research. 2024.
3. Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews. 2018;(3):CD012182.